Correction:Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma

Correction: Journal of Nanobiotechnology (2024) 22:338 10.1186/s12951-024-02579-1

In this article the wrong figure appeared as Fig. 6: author corrections in the title of the graph in panel E and in the image in panel H were not implemented due to a typesetting mistake. Figure 6 should have appeared as shown below.

Fig. 6.

Combining BT-NPs@PLEL with anti-PD-L1 treatment for inhibition in residual tumors after iRFA. A Schematic representation of treatment of residual tumor after iRFA in C57/BL6 mice. B Bioluminescence images of mice with residual tumors after iRFA after different treatments on days 0, 10, and 20 (n = 3). C Bioluminescence signals of mice in each group on day 0, 10, and 20 (n = 3). D Tumor volume of residual tumors after iRFA in different groups(n = 6). E The weight of residual tumors on day 21 after different treatments (n = 6). F Survival analysis of experimental mice in different groups (n = 6). G Representative Flow cytometry plots and proportions of CD8+ T cells on day 7 (n = 6). H Representative flow cytometry plots and proportions of Granzyme B+ cells on day 7 (n = 6). ns, not significant *p < 0.05, **p < 0.01, ***p < 0.001

Uncorrected figure

Corrected figure

The original article has been corrected. The publisher apologises to the authors and readers for the inconvenience caused by this error.